Table 1.
Clinical characteristics, parameters of disease activity and bone health.
Table 2.
Altered parameters of bone metabolism [altered bone specific alkaline phosphatase (BAP) or alkaline phosphatase (SAP), elevated parathyroid hormone (PTH), altered urinary N-terminal telopeptide (NTX) or urinary deoxypyridinoline (DPD)] and presence of bone pain in patients.
Figure 1.
Serum levels of 25-OH vitamin D levels positively correlate with calcium to creatinine ratio in urine (P = 0.03, r = 0.36) in patients with hemolytic anemia.
The predicted values based on bivariate regression are indicated as solid line.
Figure 2.
Serum 25-OH vitamin D levels are significantly lower in patients who report bone pain (back pain and/or knee pain with exercise) than in patients without reported bone pain (left).
Statistically significant differences between the groups, determined via Mann-Whitney test, are indicated with asterisks (*: P<0.05).
Figure 3.
Parameters of bone remodeling are altered in patients with sickle cell disease.
Distribution (lines indicate mean and standardvariation) of A) osteocalcin and B) RANKL/OPG ratio in patients with sickle cell disease (HbSS. grey circles) and in patients with spherocytosis (Spherocytosis, black squares) compared to age- and sex-matched healthy controls (Healthy controls, lightgrey triangles) Statistically significant differences between the groups (as assessed by Mann Whithey-U test with Bonferroni-Holm correction for multiple testing) are indicated with asterisks (*: P<0.05, **: P<0.01, ***: P<0.001).